Fidaxomicin: Difimicin; Lipiarmycin; OPT 80; OPT-80; PAR 101; PAR-101.
Fidaxomicin, an RNA polymerase inhibitor, is being developed by Optimer and Par Pharmaceuticals as a narrow-spectrum antibacterial for the treatment of Clostridium difficile infections. It is currently in phase III development with promising results so far. This review looks at the development history and scientific profile of this drug to date.
D000617:Aminoglycosides / Q000494:pharmacology* / Q000627:therapeutic use*; D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use*; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D003015:Clostridium Infections / Q000188:drug therapy*; D012321:DNA-Directed RNA Polymerases / Q000037:antagonists & inhibitors; D015507:Drugs, Investigational / Q000494:pharmacology / Q000627:therapeutic use; D000077732:Fidaxomicin; D006801:Humans; D008826:Microbial Sensitivity Tests
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D015507:Drugs, Investigational; D012321:DNA-Directed RNA Polymerases; D000077732:Fidaxomicin